{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-005120","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.888269+00:00","generated_at":"2026-06-27T19:30:22.827280+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Solid Biosciences reports $210M cash, advances DMD gene therapies; names Ian Smith Executive Chair","bullets":["Preliminary, unaudited cash and investments of ~$210M as of Dec 31, 2021.","Ninth patient dosed in IGNITE DMD Phase I/II trial for SGT-001 in Nov 2021 using second-gen manufacturing.","Plans to share additional SGT-001 expression, functional, pulmonary data in H1 2022.","SGT-003 IND-enabling studies in 2022; IND filing targeted early 2023.","Board Chair Ian F. Smith appointed Executive Chair effective Jan 10, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-005120","json":"https://secwatch.observer/filing/0001193125-22-005120.json","markdown":"https://secwatch.observer/filing/0001193125-22-005120.md","text":"https://secwatch.observer/filing/0001193125-22-005120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312522005120/0001193125-22-005120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312522005120/d289427d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:30:22.827280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}